Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
about
Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein.Recent Advances in Lentiviral Vaccines for HIV-1 InfectionIn situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancerHuman dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens.Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in miceEffects of herpes simplex virus amplicon transduction on murine dendritic cells.Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection.HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs.Vaccines and immunotherapeutics for the treatment of malignant diseaseConventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.Analysis of the role of tripeptidyl peptidase II in MHC class I antigen presentation in vivoDesigning the optimal vaccine: the importance of cytokines and dendritic cells.Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunityInduction of primary anti-HIV CD4 and CD8 T cell responses by dendritic cells transduced with self-inactivating lentiviral vectors.Effects of Olig2-overexpressing neural stem cells and myelin basic protein-activated T cells on recovery from spinal cord injuryImmunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccinesFrom pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy.Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials.Induction of T cell immunity by cutaneous genetic immunization with recombinant lentivectorLentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.DC-based cancer vaccines.Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunizationLentivirus as a potent and mechanistically distinct vector for genetic immunizationRecombinant lentivector as a genetic immunization vehicle for antitumor immunity.Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response.Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.Directing dendritic cell immunotherapy towards successful cancer treatment.Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy.New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Targeting lentiviral vectors for cancer immunotherapy.
P2860
Q24815731-F932A25D-C766-4B1E-83C0-A12F293BB543Q26742169-50FDE4C4-0116-4ECC-9E8E-1C1AEFB3B6DDQ28390899-321B6968-7E65-43A7-AC14-9B61A9A851BEQ30426385-079CC315-488D-4C91-8217-C8ACDA6386A4Q33470219-3FB53F98-A2FC-4A43-9EDB-F7D75D6EC137Q33604567-2F774EC6-F367-4356-9D7F-2C5FCF0C6A8FQ33688447-CDF4BBF6-20CC-4F57-AD3C-8DBE27089076Q33756770-E6346072-3876-4B06-990A-98BE859823BEQ33877397-7798BA27-FE1C-4745-A1CA-CC52C0B16E41Q33931602-13BF36AE-AD21-497C-BF10-B8B26D0587FDQ34170074-6D2233E6-2083-40C3-ADA1-45312A43DFCEQ34767725-F257E9D3-6775-4650-9496-308A6AD0F575Q34801021-A4BA55C5-9B44-4840-B159-6E0F2164F51CQ34801069-BAAFF595-3AAF-4642-B504-62E25570EF1CQ34801323-26777255-269F-41C4-B1C7-2EEEE0E587D3Q34958663-F05D9D30-464C-43CA-A95B-C33EDB6B1819Q35041080-C0B6A37E-F87E-4528-A152-EB877359A22DQ35146556-D4DA73A9-2126-4C23-82D0-F20F6D015CE9Q35147489-675919FC-9E0E-4ED2-BF34-E8CE075B29CAQ35543558-B393697B-26CB-4564-8DA7-C10F395CB289Q35751773-DDE1E902-2FCD-45C9-A740-9D90B5732A92Q35913786-27144DF0-5B36-40E5-9985-0130BA8716E4Q35982675-764D4CB8-1AD1-41FB-AF6C-6758EF16A55BQ36220691-F2259FF7-83D9-4E3C-88C7-A6F48895C7E4Q36313253-78DC416B-4C5B-4969-91B7-1D42157CDCF4Q36689038-85D97E6B-AA71-4D61-B547-6671C18C78AAQ36751598-2FA10AB0-1E41-4A58-84E3-9369223D8088Q36760023-50A43B38-DE39-46C6-807C-FD24F0664E43Q36809780-FBEDA62A-CC48-45E4-B14F-B0A39DD7A4D6Q36863949-10D05996-0C43-42BB-8099-74073E1512A0Q36969195-5411D769-EC00-48E5-8A6E-B25BDCE8576FQ37123441-E96A08B4-02AF-4F8D-BC18-035E53360250Q37173478-786280B1-0524-44CF-B6B0-5DFB47CAC71DQ37225212-791EBBCD-B188-493B-9019-796E69F78A4BQ37249394-38566D42-4E83-413C-B4BC-1E840D0A22B4Q37440696-06ABDB66-345B-45AE-BFC4-AB1102888B7FQ37754014-7CDA9414-058F-4CA7-AEE3-05C5CCD74EA9Q37793233-1F2401A2-EE65-474A-824B-8BDB6ACF8514Q37820489-3A0552DD-A452-4A23-B6B4-5867C82A9B25Q38043924-02AF7E86-1AB7-47E7-93E3-24B6CACDF0A6
P2860
Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Immunization with lentiviral v ...... nses and therapeutic immunity.
@en
Immunization with lentiviral v ...... nses and therapeutic immunity.
@nl
type
label
Immunization with lentiviral v ...... nses and therapeutic immunity.
@en
Immunization with lentiviral v ...... nses and therapeutic immunity.
@nl
prefLabel
Immunization with lentiviral v ...... nses and therapeutic immunity.
@en
Immunization with lentiviral v ...... nses and therapeutic immunity.
@nl
P2093
P1476
Immunization with lentiviral v ...... nses and therapeutic immunity.
@en
P2093
Jiying Zhang
Louis D Falo
Paul Robbins
P304
P356
10.4049/JIMMUNOL.174.6.3808
P407
P577
2005-03-01T00:00:00Z